Pirfenidone prevents rat esophageal stricture formation

Journal of Surgical Research

Volumn 194, Issue 2, 2015, Pages 558-564

  Orozco Perez, J ^a   Aguirre Jauregui, O ^a   Salazar Montes, A M ^b   Sobrevilla Navarro, A A ^b   Lucano Landeros, M S ^b   Armendariz Borunda J ^b,c  

^a HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c INNOVARE   (Mexico)

Author keywords

Caustic esophageal stenosis; Fibrogenic esophageal stenosis; Pirfenidone; RT PCR; Sirius red stain

Indexed keywords

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE A; PIRFENIDONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; ANTINEOPLASTIC AGENT; CTGF PROTEIN, RAT; PYRIDONE DERIVATIVE; SODIUM HYDROXIDE; TGFB1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DENSITOMETRY; DRUG EFFICACY; ESOPHAGOGRAPHY; ESOPHAGOSCOPY; ESOPHAGUS BURN; ESOPHAGUS INJURY; ESOPHAGUS STENOSIS; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; ESOPHAGEAL STENOSIS; ESOPHAGITIS; FIBROSIS; GENE EXPRESSION; METABOLISM; PATHOLOGY; PRECLINICAL STUDY; WISTAR RAT; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS; CONNECTIVE TISSUE GROWTH FACTOR; DRUG EVALUATION, PRECLINICAL; ESOPHAGEAL STENOSIS; ESOPHAGITIS; FIBROSIS; GENE EXPRESSION; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRIDONES; RATS, WISTAR; SODIUM HYDROXIDE; TRANSFORMING GROWTH FACTOR BETA1; WOUND HEALING;

EID: 84924858620     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2014.11.009     Document Type: Article

References (28)

1. A.C. Bronstein, D.A. Spyker, L.R. Cantilena, B.H. Rumack Jr, and R.C. Dart 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th annual report Clin Toxicol 50 2012 911
2. C.A. Sánchez-Ramírez, A. Larrosa-Haro, E.M. Vásquez-Garibay, and R. Macías-Rosales Socio-demographic factors associated with caustic substance ingestion in children and adolescents Int J Pediatr Otorhinolaryngol 76 2012 253
3. Z. Turkyilmaz, K. Sönmez, and A. Demirtola Mitomycin C prevents strictures in caustic esophageal burns in rats J Surg Res 123 2005 182
4. O. Herek, M. Karabul, C. Yenisey, and M. Erkuş Protective effects of ibuprofen against caustic esophageal burn injury in rats Pediatr Surg Int 26 2010 721
5. F. Larios-Arceo, G.G. Ortiz, and M. Huerta Protective effects of melatonin against caustic esophageal burn injury in rats J Pineal Res 45 2008 219
6. S.N. Iyer, J.S. Wild, M.J. Schiedt, D.M. Hyde, S.B. Margolin, and S.N. Giri Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters J Lab Clin Med 125 1995 779
7. Z.Z. Peng, G. Hu, and H. Shen Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells Nephrology (Carlton) 14 2009 565
8. A. Salazar-Montes, L. Ruiz-Corro, A. López-Reyes, E. Castrejón-Gómez, and J. Armendáriz-Borunda Potent antioxidant role of pirfenidone in experimental cirrhosis Eur J Pharmacol 595 2008 69
9. J. Armendariz-Borunda, I. Lyra-Gonzalez, and D. Medina-Preciado A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients Ann Plast Surg 68 2012 22
10. X.L. Tian, W. Yao, Z.J. Guo, L. Gu, and Y.J. Zhu Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina Chin Med Sci J 21 2006 145
11. K. Choi, L. Kihwang, R. Seung-Wook, I. Minju,-K. Koung Hoon, and C. Chulhee Pirfenidone inhibits transforming growth factor-beta1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19 Mol Vis 18 2012 1010
12. P. Gehanno, and C. Guedon Inhibition of experimental esophageal lye strictures by penicillamine Arch Otolaryngol 107 1981 145
13. E. Vardar, R. Vardar, and V. Yükselen Image-based assessment of esophageal stricture in experimental corrosive esophagitis in animals: an objective, adjunct diagnostic tool Turk J Gastroenterol 20 2009 3
14. P. Chomzynsky, and N. Sacchi Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal Biochem 162 1987 156
15. User Bulletin #02 ABI PRISM 7700 sequence detection system December 11, 1997. Available from: http://dna-.intmed.uiowa.edu/RealtimePCRdocs/Bulletin%202%20Applied%20Byosistem. Accessed January 2012.
16. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 25 2001 402
17. C.M. Johnson, and M.T. Brigger The public health impact of pediatric caustic ingestion injuries Arch Otolaryngol Head Neck Surg 138 2012 1111
18. C.F. Chang, S.P. Kuo, and H.C. Lin Endoscopic balloon dilatation for esophageal strictures in children younger than 6 years: experience in a medical center Pediatr Neonatol 52 2011 196
19. C. Zhang, X. Zhou, L. Yu, J. Ding, and R. Shi Endoscopic therapy in the treatment of caustic esophageal stricture: a retrospective case series study Dig Endosc 25 2013 490
20. C. Butler, J.W. Madden, W.M. Davis, and E.E. Peacock Jr. Morphologic aspects of experimental esophageal lye strictures. II. Effects of steroid hormones, bougienage and induced lathyrism on acute lye burns Surgery 81 1977 431
21. E. Gunel, F. Cxaglayan, O. Cxaglayan, A. Canbilen, and M. Tosun Effect of antioxidant therapy on collagen synthesis in corrosive esophageal burns Pediatr Surg Int 18 2002 24
22. S. Uhlen, P. Fayoux, and F. Vachin Mitomycin C: an alternative conservative, treatment for refractory esophageal stricture in children? Endoscopy 38 2006 404
23. L. García, I. Hernández, and A. Sandoval Pirfenidone effectively reverses experimental liver fibrosis J Hepatol 37 2002 797
24. W. Yeming, S. Somme, S. Chenren, J. Huiming, Z. Ming, and D.C. Liu Balloon catheter dilatation in children with congenital and acquired esophageal anomalies J Pediatr Surg 37 2002 398
25. T. Shimizu, T. Kuroda, and S. Hata Pirfenidone improves renal function and fibrosis in the post-obstructed kidney Kidney Int 54 1998 99
26. G. Ragha, W.C. Johnson, and D. Lockhart Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone Am J RespiR Crit Care Med 159 1999 1061
27. E.V. Veras-Castillo, L. Cardenas-Camarena, and I. Lyra-Gonzalez Controlled clinical Ann Plast Surg 70 2011 16
28. L. Flores-Contreras, A.S. Sandoval-Rodriguez, and M.G. Mena-Enriquez Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C BMC Gastroenterol 14 2014 131